JP2010511633A5 - - Google Patents

Download PDF

Info

Publication number
JP2010511633A5
JP2010511633A5 JP2009539541A JP2009539541A JP2010511633A5 JP 2010511633 A5 JP2010511633 A5 JP 2010511633A5 JP 2009539541 A JP2009539541 A JP 2009539541A JP 2009539541 A JP2009539541 A JP 2009539541A JP 2010511633 A5 JP2010511633 A5 JP 2010511633A5
Authority
JP
Japan
Prior art keywords
formulation
dosage form
enhancer
topiramate
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009539541A
Other languages
English (en)
Japanese (ja)
Other versions
JP5721326B2 (ja
JP2010511633A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/086391 external-priority patent/WO2008070670A2/en
Publication of JP2010511633A publication Critical patent/JP2010511633A/ja
Publication of JP2010511633A5 publication Critical patent/JP2010511633A5/ja
Application granted granted Critical
Publication of JP5721326B2 publication Critical patent/JP5721326B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009539541A 2006-12-04 2007-12-04 トピラマートの増強即時放出配合物 Expired - Fee Related JP5721326B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87249706P 2006-12-04 2006-12-04
US60/872,497 2006-12-04
PCT/US2007/086391 WO2008070670A2 (en) 2006-12-04 2007-12-04 Enhanced immediate release formulations of topiramate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015008599A Division JP5974122B2 (ja) 2006-12-04 2015-01-20 トピラマートの増強即時放出配合物

Publications (3)

Publication Number Publication Date
JP2010511633A JP2010511633A (ja) 2010-04-15
JP2010511633A5 true JP2010511633A5 (enExample) 2010-09-02
JP5721326B2 JP5721326B2 (ja) 2015-05-20

Family

ID=39493041

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009539541A Expired - Fee Related JP5721326B2 (ja) 2006-12-04 2007-12-04 トピラマートの増強即時放出配合物
JP2015008599A Expired - Fee Related JP5974122B2 (ja) 2006-12-04 2015-01-20 トピラマートの増強即時放出配合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015008599A Expired - Fee Related JP5974122B2 (ja) 2006-12-04 2015-01-20 トピラマートの増強即時放出配合物

Country Status (9)

Country Link
US (2) US20080131501A1 (enExample)
EP (2) EP2061431B1 (enExample)
JP (2) JP5721326B2 (enExample)
CN (3) CN102114002B (enExample)
AU (1) AU2007329373B2 (enExample)
CA (1) CA2658521C (enExample)
ES (2) ES2422655T3 (enExample)
MX (1) MX2009003911A (enExample)
WO (1) WO2008070670A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
ES2312308T3 (es) * 2006-11-17 2013-03-26 Supernus Pharmaceuticals, Inc. Formulaciones de liberación sostenida de topiramato
JP5424571B2 (ja) * 2007-04-12 2014-02-26 協和発酵キリン株式会社 トピラマート含有固形製剤
US20120107393A1 (en) * 2010-10-29 2012-05-03 University Of Tennessee Research Foundation Pellets for Delivery of Biologically Active Substances
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
HK1213473A1 (zh) 2013-03-15 2016-07-08 阿普雷奇亚制药有限责任公司 托吡酯的快速分散劑型
WO2014167439A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Modified release pharmaceutical compositions of topiramate or salts thereof
JP6207291B2 (ja) * 2013-08-07 2017-10-04 大同化成工業株式会社 外用剤用組成物
CN104188920A (zh) * 2014-07-28 2014-12-10 安徽省逸欣铭医药科技有限公司 托吡酯颗粒剂及其制备方法
CN104402705B (zh) * 2014-11-04 2017-04-12 成都理工大学 球形柠檬酸钙及其制备方法和应用
CN104586871B (zh) * 2014-12-27 2018-01-16 北京罗诺强施医药技术研发中心有限公司 包含托吡酯的药物组合物
CN104922075A (zh) * 2015-05-31 2015-09-23 黑龙江佰彤儿童药物研究有限公司 一种治疗儿童癫痫的固体制剂及其制备方法
FR3048616B1 (fr) * 2016-03-14 2018-04-06 Polyneuros Polycomplexes de composes poly-lysine pour la prevention et/ou la lutte contre la sclerose laterale amyotrophique
KR102441382B1 (ko) 2016-09-30 2022-09-07 (주)아모레퍼시픽 벤조산아마이드 화합물 및 용해보조제를 포함하는 조성물
KR102359439B1 (ko) 2017-03-31 2022-02-09 (주)아모레퍼시픽 벤조산아마이드 화합물 및 사이클로덱스트린 용해보조제를 포함하는 조성물
KR102506882B1 (ko) 2017-11-30 2023-03-08 (주)아모레퍼시픽 벤조산아마이드 화합물 및 용해보조제를 포함하는 조성물
CN108379588B (zh) * 2018-03-05 2024-07-02 合肥合源药业有限公司 托吡酯组合物
KR102623441B1 (ko) 2018-10-31 2024-01-11 (주)아모레퍼시픽 벤조산아마이드 화합물 및 용해보조제를 포함하는 조성물
EP3883546A1 (en) 2018-11-21 2021-09-29 Rosemont Pharmaceuticals Ltd Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
EP3955905A4 (en) * 2019-04-18 2023-05-31 Prevep LLC THERAPEUTIC COMBINATIONS, LIQUID PHARMACEUTICAL COMPOSITIONS, KITS FOR THEIR PREPARATION AND PROCESSES FOR THEIR USE
WO2022181569A1 (ja) * 2021-02-24 2022-09-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 口腔内崩壊性組成物、カプセル剤、フィルムコーティング錠、フィルム製剤及び口腔内崩壊性の向上方法
JP2023084842A (ja) * 2021-12-08 2023-06-20 大阪瓦斯株式会社 複合体、組成物、塗料、吸収剤、及び組成物の製造方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
TW349870B (en) 1993-09-30 1999-01-11 Janssen Pharmaceutica Nv An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5576311A (en) * 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
US5998380A (en) 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
US5753693A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5935933A (en) 1997-07-16 1999-08-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain
US5760007A (en) 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
US20040028735A1 (en) * 1997-11-14 2004-02-12 Unchalee Kositprapa Pharmaceutical formulation
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
US6524620B2 (en) * 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
AU770645B2 (en) * 1998-11-02 2004-02-26 Alkermes Pharma Ireland Limited Multiparticulate modified release composition
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
AU771388B2 (en) 1999-01-19 2004-03-18 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating cluster headaches
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
NZ514812A (en) * 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in lowering blood pressure
US7056890B2 (en) * 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
WO2001013904A2 (en) * 1999-08-20 2001-03-01 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
US6479467B1 (en) * 1999-12-16 2002-11-12 Eastman Chemical Company Cyclodextrin ethers
SE0000601D0 (sv) * 2000-02-24 2000-02-24 Jan Hedner Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
CN101404993A (zh) * 2000-07-07 2009-04-08 奥索-麦克尼尔药品公司 用于预防ii型糖尿病和x综合征的发展的抗惊厥剂衍生物
US6191117B1 (en) 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
AU2002253838B2 (en) * 2000-10-30 2006-11-09 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising anti-diabetic and anticonvulsant agents
EP1345602B1 (en) * 2000-11-30 2010-07-21 Novodermix International Limited Wound healing
TWI321054B (en) * 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20030072802A1 (en) * 2001-10-11 2003-04-17 R.T. Alamo Ventures, Inc. Sustained release topiramate
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US7815936B2 (en) * 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
KR101008326B1 (ko) * 2002-02-26 2011-01-13 오르토-맥네일 파마슈티칼, 인코퍼레이티드 항경련제 유도체 및 항-편두통제를 포함하는 편두통치료를 위한 공-요법
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
CA2494233A1 (en) * 2002-07-29 2004-02-05 Alza Corporation Formulations and dosage forms for controlled delivery of topiramate
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
WO2004022037A1 (en) * 2002-09-04 2004-03-18 Ranbaxy Laboratories Limited Taste masked dosage forms and processes for their preparation
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
RU2005122008A (ru) * 2002-12-13 2006-02-10 Цилаг Аг (Ch) Препараты с контролируемым высвобождением, содержащие трамадол и топирамат
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
JP4469846B2 (ja) * 2003-01-31 2010-06-02 エラン ファーマ インターナショナル，リミティド ナノ粒子状トピラメート製剤
MXPA06001548A (es) * 2003-08-06 2006-09-04 Johnson & Johnson Suministro uniforme de topiramato durante un periodo prolongado con formulaciones de dispersion.
US20050136108A1 (en) * 2003-08-22 2005-06-23 Yam Noymi V. Stepwise delivery of topiramate over prolonged period of time
US20050069587A1 (en) * 2003-09-02 2005-03-31 Modi Nishit Bachulal Novel drug compositions and dosage forms of topiramate
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
US7611728B2 (en) * 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
DE602004032149D1 (de) * 2003-09-26 2011-05-19 Alza Corp Oros-push-stick für die kontrollierte abgabe von wirkstoffen
DE602004030931D1 (enExample) * 2003-11-04 2011-02-17 Supernus Pharmaceuticals Inc
MXPA06005461A (es) * 2003-11-13 2006-12-15 Johnson & Johnson Dispersiones de mezclas en estado fundido que comprenden un farmaco de baja solubilidad en agua y un copolimero de bloque de oxido de etileno-oxido de propileno.
US7387793B2 (en) * 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20050129765A1 (en) * 2003-11-14 2005-06-16 Shaoling Li Controlled release of topiramate in liquid dosage forms
JP4994039B2 (ja) * 2003-11-26 2012-08-08 スパーナス ファーマシューティカルズ インコーポレイテッド 脂溶性または疎水性化合物の送達に有用なミセル系
CN1905856A (zh) * 2003-12-23 2007-01-31 阿尔扎公司 用于增加受控递送的药物组合物的溶解度的方法和剂型
MXPA06007510A (es) * 2003-12-29 2009-06-10 Johnson & Johnson Composiciones de farmaco y formas de dosis novedosas de topiramato.
JP2008507508A (ja) * 2004-07-22 2008-03-13 株式會社アモーレパシフィック トピラメート徐放性製剤及びその製造方法
EP1802286B1 (en) * 2004-08-04 2008-07-23 ALZA Corporation Sustained drug release composition demonstrating an ascending zero order release pattern, methods of manufacturing such a composition
US20060105045A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
WO2006063078A2 (en) * 2004-12-08 2006-06-15 Elan Corporation, Plc Topiramate pharmaceuticals composition
US20060233892A1 (en) * 2005-04-19 2006-10-19 Curt Hendrix Topiramate compositions for treatment of headache
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
ES2312308T3 (es) * 2006-11-17 2013-03-26 Supernus Pharmaceuticals, Inc. Formulaciones de liberación sostenida de topiramato

Similar Documents

Publication Publication Date Title
JP2010511633A5 (enExample)
AU2007329373B2 (en) Enhanced immediate release formulations of topiramate
JP2010510241A5 (enExample)
ES2312308T1 (es) Formulaciones de liberacion sostenida de topiramato.
KR20120031002A (ko) 비-아편계 및 아편계 진통제의 조합을 포함하는 구강붕해정 조성물
JP2011037876A5 (enExample)
JP2004505918A5 (enExample)
JP2016518398A (ja) 低用量医薬組成物
JP6820116B2 (ja) レボセチリジンを含む医薬組成物
SG186182A1 (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate
CN101784260A (zh) 包含二氢吡啶钙通道拮抗剂的药物组合物及其制备方法
JP6320371B2 (ja) エンテカビルの医薬組成物および製造方法
RU2342926C2 (ru) Способ получения низкокристаллического олтипраза или аморфного олтипраза
TW201410267A (zh) 延長釋放左乙拉西坦和製備方法
WO2012029838A1 (ja) 口腔内崩壊錠
WO2014193528A1 (en) Amorphous dosage forms and methods
JP2012041293A (ja) 乳酸菌又はその抽出成分を含有する口腔内崩壊錠
JP4022269B2 (ja) 医薬組成物
JP2016006025A (ja) 医薬用組成物及びその製造方法、並びに口腔内崩壊錠及びその製造方法
JP2005263816A (ja) 塩酸ベニジピン含有医薬組成物
JP2013043834A (ja) 溶出改善固形製剤
JPWO2005018607A1 (ja) 溶解性を改善した医薬品製剤
WO2007064084A1 (en) Granules containing pranlukast and processes for the preparation thereof
JP3184239B2 (ja) 矯味経口用医薬組成物
WO2020048449A1 (zh) 包含1,3,5-三嗪衍生物或其盐的固体药物组合物